Does Rallies show 13F holders for ATYR?

Yes. Rallies tracks hedge fund and 13F ownership data for ATYR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ATYR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATYR. It does not provide personalized investment advice.

ATYR (aTyr Pharma, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

aTyr Pharma, Inc. Common Stock (ATYR) is a publicly traded Healthcare sector company. As of May 21, 2026, ATYR trades at $0.54 with a market cap of $50.94M and a P/E ratio of -0.67. ATYR moved +10.04% today. Year to date, ATYR is -28.87%; over the trailing twelve months it is -84.80%. Its 52-week range spans $0.40 to $7.29. Analyst consensus is neutral with an average price target of $7.33. Rallies surfaces ATYR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ATYR stock?

Hedge funds tracked by Rallies that own ATYR include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for aTyr Pharma, Inc. Common Stock.

ATYR Key Metrics

Key financial metrics for ATYR
Metric	Value
Price	$0.54
Market Cap	$50.94M
P/E Ratio	-0.67
EPS	$-0.80
Dividend Yield	0.00%
52-Week High	$7.29
52-Week Low	$0.40
Volume	10.84K
Avg Volume	0
Revenue (TTM)	$190.00K
Net Income	$-74.12M
Gross Margin	0.00%

Top Hedge Funds Holding ATYR

Exoduspoint Capital holds 48.23K shares of ATYR, changed +187.30% as of Mar 31, 2025.

Latest ATYR News

Atyr Pharma reports $10.8M Q1 loss, eyes June Phase 3 IND — May 15, 2026
aTyr Pharma Plans June IND Submission for 372-Patient Phase 3 Efzofitimod Trial — May 11, 2026
Atyr Pharma Beats Q4 Loss Estimates, Schedules FDA Meeting on Phase 3 Efzofitimod — Mar 5, 2026

Recent ATYR Insider Trades

Shukla Sanjay sold 3.75K (~$3.66K) on Feb 4, 2026.
Broadfoot Jill Marie sold 1.56K (~$1.52K) on Feb 4, 2026.
DENYES NANCY sold 1.12K (~$1.09K) on Feb 4, 2026.

ATYR Analyst Consensus

5 analysts cover ATYR: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.33.

Common questions about ATYR

Who owns ATYR stock?: Hedge funds tracked by Rallies that own ATYR include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for aTyr Pharma, Inc. Common Stock.
Does Rallies show 13F holders for ATYR?: Yes. Rallies tracks hedge fund and 13F ownership data for ATYR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ATYR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATYR. It does not provide personalized investment advice.